U Marschall1, B Arnold, W Häuser. 1. Hauptabteilung Unternehmensstrategie, BARMER GEK Hauptverwaltung, Wuppertal.
Abstract
BACKGROUND: The data available on the types of treatment delivered and healthcare costs of fibromyalgia syndrome (FMS) patients in Germany are currently not representative. MATERIAL AND METHODS: The data from all 6,897,846 insured persons of the German statutory health insurance company Barmer Ersatzkasse (BEK) before the fusion with the Gmünder Ersatzkasse (GEK) were analyzed if more than 2 billing cases with the diagnosis M79.7 were found (FMS cases) in the 8 consecutive quarter years of 2007-2008. In these cases the types and costs of out-patient treatment as well as the operation and procedure key (OPS) classification of in-patient treatment in cases of any discharge diagnosis of FMS were analyzed. RESULTS: A diagnosis of FMS was recorded in 14,870 insured persons in out-patient care and in 6130 in-patients from 1(st) January 2008 to 31(st) December 2009. The 1-year prevalence of FMS diagnosis was 19,592 of the patients (0.3%). Non-steroidal agents were prescribed in 48%, weak opioids in 21% and strong opioids in 11% of the out-patients with FMS. Out-patient psychotherapy was conducted in 8% of the FMS cases. In 31% of the cases hospital treatment was carried out of which 14% received multicomponent therapy. The average healthcare costs were 4,331 <euro> per year. CONCLUSION: The data of the BEK document high healthcare costs and treatment which is mainly not in line with the recommendations of the German guidelines on the management of FMS.
BACKGROUND: The data available on the types of treatment delivered and healthcare costs of fibromyalgia syndrome (FMS) patients in Germany are currently not representative. MATERIAL AND METHODS: The data from all 6,897,846 insured persons of the German statutory health insurance company Barmer Ersatzkasse (BEK) before the fusion with the Gmünder Ersatzkasse (GEK) were analyzed if more than 2 billing cases with the diagnosis M79.7 were found (FMS cases) in the 8 consecutive quarter years of 2007-2008. In these cases the types and costs of out-patient treatment as well as the operation and procedure key (OPS) classification of in-patient treatment in cases of any discharge diagnosis of FMS were analyzed. RESULTS: A diagnosis of FMS was recorded in 14,870 insured persons in out-patient care and in 6130 in-patients from 1(st) January 2008 to 31(st) December 2009. The 1-year prevalence of FMS diagnosis was 19,592 of the patients (0.3%). Non-steroidal agents were prescribed in 48%, weak opioids in 21% and strong opioids in 11% of the out-patients with FMS. Out-patient psychotherapy was conducted in 8% of the FMS cases. In 31% of the cases hospital treatment was carried out of which 14% received multicomponent therapy. The average healthcare costs were 4,331 <euro> per year. CONCLUSION: The data of the BEK document high healthcare costs and treatment which is mainly not in line with the recommendations of the German guidelines on the management of FMS.
Authors: C Sommer; W Häuser; M Berliner; W Brückle; S Ehlers; K Mönkemöller; B Moradi; F Petzke; N Uçeyler; R Wörz; E Winter; D O Nutzinger Journal: Schmerz Date: 2008-06 Impact factor: 1.107
Authors: W Häuser; S Schild; M Kosseva; S Hayo; H von Wilmowski; R Alten; J Langhorst; W Hofmann; J Maus; H Glaesmer Journal: Schmerz Date: 2010-06 Impact factor: 1.107
Authors: B Arnold; W Häuser; K Bernardy; W Brückle; E Friedel; V Köllner; H Kühn-Becker; M Richter; M Weigl; T Weiss; M Offenbächer Journal: Schmerz Date: 2008-06 Impact factor: 1.107
Authors: Brian Walitt; Gerard Urrútia; María Betina Nishishinya; Sarah E Cantrell; Winfried Häuser Journal: Cochrane Database Syst Rev Date: 2015-06-05
Authors: W Eich; K-J Bär; M Bernateck; M Burgmer; C Dexl; F Petzke; C Sommer; A Winkelmann; W Häuser Journal: Schmerz Date: 2017-06 Impact factor: 1.107
Authors: A Galek; B Erbslöh-Möller; V Köllner; H Kühn-Becker; J Langhorst; F Petermann; U Prothmann; A Winkelmann; W Häuser Journal: Schmerz Date: 2013-06 Impact factor: 1.107